Clinical Trials Arena on MSN
Agomab’s ALK5 inhibitor to advance to Phase IIb in Crohn’s disease
Ontunisertib could become the first FDA-approved anti-fibrotic suitable for Crohn’s disease patients with symptomatic ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback